The deal allows Merck to take over development of privately held LaNova Medicines' LM-299, the companies said on Thursday.
Pharmaceutical Technology on MSN4d
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
Zacks.com on MSN4d
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMerck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback